Health Economics›Follicular lymphoma›Advanced disease first-line therapy randomized data

Advanced disease first-line therapy randomized data

Follicular lymphoma · 16 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Lenalidomide and Rituximab (R2) Variant #08	—	R 134 502	28d	—	—	11	R 396 684 PFS proxy	1
Bendamustine and Obinutuzumab Variant #02	—	R 107 792	28d	—	—	~5	~R 227 981 PFS proxy · indirect	2
G-CHOP Variant #01	—	R 96 436	21d	—	—	~8	~R 246 819 indirect	—
G-CVP Variant #01	—	R 95 929	21d	—	—	~8	~R 242 761 indirect	—
R-CHVP+I Variant #01	—	R 78 575	28d	—	—	~6	~R 160 596 indirect	—
R-FND Variant #01	—	R 38 088	30d	—	—	~4	~R 152 353 indirect	—
R-FM Variant #01	—	R 37 828	28d	—	—	~8	~R 278 777 indirect	—
Bendamustine and Rituximab (BR) Variant #01	—	R 33 874	28d	—	—	8	R 270 994 PFS proxy	1
R-MCP Variant #01	—	R 32 758	28d	—	—	~8	~R 262 060 indirect	—
R-CHOP Variant #08	—	R 26 946	21d	44.4 mo	—	6	R 109 868 PFS proxy	2
R-CVP Variant #01	—	R 26 502	21d	—	—	8	R 212 013 PFS proxy	1
Rituximab and hyaluronidase monotherapy Variant #01 Partial	—	R 25 905	28d	—	—	1	R 25 905 PFS proxy	1
Chlorambucil monotherapy Variant #03	—	R 2 355	28d	~12.6 mo	~69.7 mo	~13	~R 30 610 PFS proxy · indirect	6
Cyclophosphamide monotherapy Variant #01	—	R 1 680	28d	—	~15.8 mo	~1	~R 1 680 PFS proxy · indirect	1
Rituximab monotherapy Variant #09 Partial	—	—	28d	~11.0 mo	—	~1	—	6
Watchful waiting Partial	—	—	—	~12.9 mo	—	—	—	—

16 of 16 regimens shown